Phase 3 trial of APF530 versus palonosetron (PALO) in preventing chemotherapy-induced nausea and vomiting (CINV): Efficacy in breast cancer patients (pts) receiving moderately (MEC) or highly (HEC) emetogenic chemotherapy.

2014 ◽  
Vol 32 (15_suppl) ◽  
pp. 9645-9645
Author(s):  
Ralph V. Boccia ◽  
William Cooper ◽  
Erin O'Boyle
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Emetogenic Chemotherapy ◽  
Nausea And Vomiting ◽  
Breast Cancer Patients ◽  
Phase 3

scholarly journals Analysis of Antiemetic Premedication Administration Timing on Nausea and Vomiting Incidence among Breast Cancer Patients Receiving Chemotherapy

2020 ◽  
Vol 9 (4) ◽  
pp. 298
Author(s):  
Mahardian Rahmadi ◽  
Indira D. Kharismawati ◽  
Heru Purwanto ◽  
Irvina Harini ◽  
Suharjono Suharjono ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Emetogenic Chemotherapy ◽  
Nausea And Vomiting ◽  
Observational Research ◽  
Breast Cancer Patients ◽  
Specific Time ◽  
Time Pattern ◽  
Factors Affecting ◽  
Delayed Nausea

The risk factors affecting chemotherapy-induced nausea and vomiting (CINV) includes antiemetic premedication time pattern, and this study investigates the capability of enhancing this in breast cancer patients receiving high emetogenic chemotherapy (HEC). Furthermore, this observational research was implemented at the oncology unit of Dr. Soetomo General Hospital Surabaya over a three-month period involving 69 female patients. The results showed unspecific antiemetic premedication timing in comparison to those with recommended timeframes, was connected with greater occurrence of both acute nausea in all cycles of chemotherapy (p<0.05), and acute vomiting in second and third cycles (p<0.05) but not in the first cycle (p=0.49). However, specific time administration of antiemetic treatment was linked with lower incidence of delayed nausea in all cycles (p<0.05), and less delayed vomiting in second and third cycles (p<0.05) but not in first cycle (p=0.10). These findings indicate specific time administration of antiemetic drugs causes significant advantages in mitigating CINV among breast cancer patients treated with emetogenic chemotherapy, and significantly lessened the occurrence of acute and delayed nausea and vomiting.Keywords: Antiemetic premedication timing, breast cancer, CINV, nausea and vomiting Analisis Waktu Pemberian Premedikasi Antiemetik terhadap Kejadian Mual Muntah pada Pasien Kanker Payudara yang Mendapatkan Kemoterapi AbstrakKemoterapi dapat menginduksi mual muntah (chemotherapy-induced nausea and vomiting, CINV) yang dipengaruhi oleh beberapa faktor. Salah satu faktornya adalah waktu pemberian premedikasi antiemetik yang dapat meningkatkan kejadian CINV pada pasien kanker payudara yang menerima kemoterapi. Studi ini menganalisis waktu pemberian premedikasi antiemetik terhadap kejadian mual dan muntah yang terjadi pada pasien kanker payudara yang mendapatkan kemoterapi dengan tingkat emetogenik yang tinggi. Penelitian ini merupakan penelitian observasional prospektif dilakukan di Poli Onkologi Satu Atap RSUD Dr. Soetomo Surabaya selama periode pengambilan data tiga bulan dan melibatkan 69 wanita kanker payudara yang mendapat kemoterapi dengan tingkat emetogenik yang tinggi. Pemberian premedikasi antiemetik dengan waktu yang tidak spesifik, meningkatkan kejadian mual akut pada semua siklus dengan p<0,05 dan pada kejadian muntah akut pada siklus kedua dan ketiga (p<0,05), namun tidak pada siklus pertama kemoterapi (p=0,49). Pemberian premedikasi antiemetik dengan waktu spesifik dapat menurunkan kejadian mual tertunda di siklus pertama hingga ketiga (p<0,05) dan pada kejadian muntah tertunda pada siklus kedua dan ketiga (p<0,05), namun tidak pada siklus pertama (p=0,10). Penelitian ini memberikan bukti bahwa premedikasi antiemetik yang diberikan dengan waktu spesifik memberikan manfaat dalam mengurangi kejadian CINV yang berpotensi pada pasien kanker payudara yang mendapatkan kemoterapi dengan tingkat emetogenik tinggi.   Kata kunci: CINV, kanker payudara, mual dan muntah, waktu pemberian premedikasi antiemetik

scholarly journals Lipoplatin Treatment in Lung and Breast Cancer

2011 ◽  
Vol 2011 ◽  
pp. 1-7 ◽  
Author(s):  
Manuela Fantini ◽  
Lorenzo Gianni ◽  
Carlotta Santelmo ◽  
Fabrizio Drudi ◽  
Cinzia Castellani ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Overall Survival ◽  
Cancer Patients ◽  
Triple Negative ◽  
Response Rate ◽  
Toxicity Profile ◽  
Phase 2 ◽  
Breast Cancer Patients ◽  
Phase 3 ◽  
Cisplatin Analogues

The introduction of cisplatin in cancer treatment represents an important achievement in the oncologic field. Many types of cancers are now treated with this drug, and in testicular cancer patients major results are reached. Since 1965, other compounds were disovered and among them carboplatin and oxaliplatin are the main Cisplatin analogues showing similar clinical efficacy with a safer toxicity profile. Lipoplatin is a new liposomal cisplatin formulation which seems to have these characteristics. Lipoplatin was shown to be effective in NSCLC both in phase 2 and phase 3 trials, with the same response rate of Cisplatin, a comparable overall survival but less toxicity. A new protocol aiming to elucidate the double capacity of Lipoplatin to act as a chemotherapeutic and angiogenetic agent in triple-negative breast cancer patients is upcoming.

scholarly journals LEMON AROMATHERAPY AS AN ALTERNATIVE TO REDUCE THE INTENSITY OF CHEMOTHERAPY-RELATED NAUSEA AND VOMITING EXPERIENCED BY THE BREAST CANCER PATIENTS

2021 ◽  
Vol 5 (2) ◽  
pp. 125-130
Author(s):  
Puji Hastuti ◽  
Yuli Nurhayati ◽  
Dwi Ernawati ◽  
Christina Yuliastuti ◽  
Merina Widyastuti
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Sampling Technique ◽  
Complementary Therapy ◽  
Nausea And Vomiting ◽  
Wilcoxon Test ◽  
Control Group ◽  
Breast Cancer Patients ◽  
Post Test ◽  
Abnormal Tissue

ABSTRACT Introduction : The mechanism of breast cancer is the cells growing and breeding become appear abnormal tissue of breast. One of the common treatments for it is chemotherapy using cytotoxic drugs. However, chemotherapy may cause nausea and vomiting as its side effects. Lemon aromatherapy is a complementary therapy in patients with breast cancer who experience nausea or vomiting. The study’s purpose was to know the effect of lemon aromatherapy on the intensity of nausea and vomiting experienced by the breast cancer patients as an effect of chemoterapy in the Chemo Center Room of RSAL Dr. Ramelan Surabaya. Material and Methods : The study was the pre-experimental design with pre-post test without control group. There are two variables, lemon aromatherapy is independent, and the intensity of nausea and vomiting is dependent. The sampling technique was nonprobability purposive sampling, with 34 breast cancer patients taken as the sample. A questionnaire was the instrument for collecting the data. The Data collected were analyzed using the Wilcoxon Test (α = 0,05). Results : The study’s result indicated that the lemon aromatherapy was effectively to decrease of the intensity of nausea and vomiting exeperienced by the respondents, with the value of Wilcoxon test p < 0.001. Conclusion : Lemon aromatherapy stimulates the raphe nucleus to produce serotonin. Which function to generate a sense of comfort and calm. For that reason, it can be used as an alternative for taking care of nausea and vomiting experienced by patients with breast cancer as the side effect of chemotherapy. Keywords:  Lemon Aromatherapy, Nausea, Vomiting, Chemotherapy  

Sign in / Sign up

Export Citation Format

Share Document